4QVX

Discovery of a Potent and Selective BCL-XL Inhibitor That Demonstrates Thrombocytopenia and Inhibits Tumor Growth in Vivo

Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.10 Å
  • R-Value Free: 0.257 
  • R-Value Work: 0.191 
  • R-Value Observed: 0.194 

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.1 of the entry. See complete history. 


Literature

Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity.

Tao, Z.F., Hasvold, L., Wang, L., Wang, X., Petros, A.M., Park, C.H., Boghaert, E.R., Catron, N.D., Chen, J., Colman, P.M., Czabotar, P.E., Deshayes, K., Fairbrother, W.J., Flygare, J.A., Hymowitz, S.G., Jin, S., Judge, R.A., Koehler, M.F., Kovar, P.J., Lessene, G., Mitten, M.J., Ndubaku, C.O., Nimmer, P., Purkey, H.E., Oleksijew, A., Phillips, D.C., Sleebs, B.E., Smith, B.J., Smith, M.L., Tahir, S.K., Watson, K.G., Xiao, Y., Xue, J., Zhang, H., Zobel, K., Rosenberg, S.H., Tse, C., Leverson, J.D., Elmore, S.W., Souers, A.J.

(2014) ACS Med Chem Lett 5: 1088-1093

  • DOI: 10.1021/ml5001867
  • Primary Citation of Related Structures:  
    4QVX

  • PubMed Abstract: 

    • A-1155463, a highly potent and selective BCL-XL inhibitor, was discovered through nuclear magnetic resonance (NMR) fragment screening and structure-based design. This compound is substantially more potent against BCL-XL-dependent cell lines relative to our recently reported inhibitor, WEHI-539, while possessing none of its inherent pharmaceutical liabilities ...

    A-1155463, a highly potent and selective BCL-XL inhibitor, was discovered through nuclear magnetic resonance (NMR) fragment screening and structure-based design. This compound is substantially more potent against BCL-XL-dependent cell lines relative to our recently reported inhibitor, WEHI-539, while possessing none of its inherent pharmaceutical liabilities. A-1155463 caused a mechanism-based and reversible thrombocytopenia in mice and inhibited H146 small cell lung cancer xenograft tumor growth in vivo following multiple doses. A-1155463 thus represents an excellent tool molecule for studying BCL-XL biology as well as a productive lead structure for further optimization.

    Organizational Affiliation: 

    AbbVie, Inc. , 1 North Waukegan Road, North Chicago, Illinois 60064 United States.



Macromolecules
Find similar proteins by: 
(by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Bcl-2-like protein 1A, B167Homo sapiensMutation(s): 0 
Gene Names: BCL2L1, BCL2L, BCLX
UniProt & NIH Common Fund Data Resources
Find proteins for Q07817 (Homo sapiens)
Explore Q07817 
Go to UniProtKB:  Q07817
PHAROS:  Q07817
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ07817
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
3CQ
Query on 3CQ
Download Ideal Coordinates CCD File 
C [auth A],
D [auth B]		2-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydroisoquinolin-2(1H)-yl]-5-(3-{4-[3-(dimethylamino)prop-1-yn-1-yl]-2-fluorophenoxy}propyl)-1,3-thiazole-4-carboxylic acid
C35 H32 F N5 O4 S2
SOYCFODXNRVBTI-UHFFFAOYSA-N		 Ligand Interaction
Binding Affinity Annotations 
IDSourceBinding Affinity
3CQ Binding MOAD:  4QVX Ki: 1.00e-2 (nM) from 1 assay(s)
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.10 Å
  • R-Value Free: 0.257 
  • R-Value Work: 0.191 
  • R-Value Observed: 0.194 
  • Space Group: C 2 2 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 73.107α = 90
b = 90.955β = 90
c = 83.736γ = 90
Software Package:
Software NamePurpose
ADSCdata collection
MOLREPphasing
BUSTER-TNTrefinement
PROCESSdata reduction
PROCESSdata scaling

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


View more in-depth experimental data

Entry History 

Deposition Data

  • Deposited Date: 2014-07-16 
  • Released Date: 2015-07-22 
    • Deposition Author(s): Park, C.H.

Revision History  (Full details and data files)

  • Version 1.0: 2015-07-22
    Type: Initial release
  • Version 1.1: 2017-07-26
    Changes: Refinement description, Source and taxonomy